• Jangsoo Suh, CTO
    I remember meeting Professor James Yoo one day in 2009. I remember that, as a scholar, he told me confidently about the future of regenerative medicine. This was the starting point for my journey along the path of regenerative medicine. While studying the diagnosis of blood disorders and transfusion medicine in hospitals, I thought about combining this field with regenerative medicine. This led me to the development of artificial bone marrow, an as-yet unrealized dream. Artificial bone marrow will one day be used as a replacement for bone marrow for patients with blood disorders who have difficulties with bone marrow transplants, and will serve as the basic framework for producing red blood cell products at an industrial level.

    When our society becomes a super-aged society, the population of blood donors will decrease and the demand for blood transfusions will increase significantly, which may lead to constant blood supply shortages in society. If a plant can produce blood products at low cost using artificial bone marrow, this problem will be solved. Recently, as the tools of regenerative medicine are also rapidly evolving, it is expected that hospitals will begin purchasing blood products from blood plants instead of blood banks in the near future.
    Now, ten years later, the path to regenerative medicine, which began with the wild dream of developing artificial bone marrow, is leading towards INNOREGEN, INC.